81 related articles for article (PubMed ID: 34544341)
21. Chemically induced degradation of epigenetic targets.
Kabir M; Yu X; Kaniskan HÜ; Jin J
Chem Soc Rev; 2023 Jul; 52(13):4313-4342. PubMed ID: 37314393
[TBL] [Abstract][Full Text] [Related]
22. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of embryonic ectoderm development in stem cell differentiation and transformation during ontogenesis.
Huang L; Li F; Ye L; Yu F; Wang C
Cell Prolif; 2023 Apr; 56(4):e13413. PubMed ID: 36727213
[TBL] [Abstract][Full Text] [Related]
24. An overview of the development of EED inhibitors to disable the PRC2 function.
Liu KL; Zhu K; Zhang H
RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495
[TBL] [Abstract][Full Text] [Related]
25. lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma.
Wozniak M; Czyz M
Front Mol Biosci; 2023; 10():1170026. PubMed ID: 37325482
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
27. Targeted protein degradation in cancers: Orthodox PROTACs and beyond.
Li J; Chen X; Lu A; Liang C
Innovation (Camb); 2023 May; 4(3):100413. PubMed ID: 37033156
[TBL] [Abstract][Full Text] [Related]
28. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma.
Thieme E; Bruss N; Sun D; Dominguez EC; Coleman D; Liu T; Roleder C; Martinez M; Garcia-Mansfield K; Ball B; Pirrotte P; Wang L; Xia Z; Danilov AV
Mol Cancer; 2023 Mar; 22(1):64. PubMed ID: 36998071
[TBL] [Abstract][Full Text] [Related]
29. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
30. Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer.
Dong GJ; Xu JL; Qi YR; Yuan ZQ; Zhao W
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076977
[TBL] [Abstract][Full Text] [Related]
31. EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis.
Wang J; Yu X; Gong W; Liu X; Park KS; Ma A; Tsai YH; Shen Y; Onikubo T; Pi WC; Allison DF; Liu J; Chen WY; Cai L; Roeder RG; Jin J; Wang GG
Nat Cell Biol; 2022 Mar; 24(3):384-399. PubMed ID: 35210568
[TBL] [Abstract][Full Text] [Related]
32. Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.
Rej RK; Wang C; Lu J; Wang M; Petrunak E; Zawacki KP; McEachern D; Yang CY; Wang L; Li R; Chinnaswamy K; Wen B; Sun D; Stuckey JA; Zhou Y; Chen J; Tang G; Wang S
J Med Chem; 2021 Oct; 64(19):14540-14556. PubMed ID: 34613724
[TBL] [Abstract][Full Text] [Related]
33. Transcriptomics-Based Repositioning of Natural Compound, Eudesmin, as a PRC2 Modulator.
Yi SA; Nam KH; Lee MG; Oh H; Noh JS; Jeong JK; Kwak S; Jeon YJ; Kwon SH; Lee J; Han JW
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577136
[TBL] [Abstract][Full Text] [Related]
34. Host genetics and gut microbiota jointly regulate blood biochemical indicators in chickens.
Jiang X; Zhang B; Lan F; Zhong C; Jin J; Li X; Zhou Q; Li J; Yang N; Wen C; Sun C
Appl Microbiol Biotechnol; 2023 Dec; 107(24):7601-7620. PubMed ID: 37792060
[TBL] [Abstract][Full Text] [Related]
35. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
Li X; Chen Y; Bai L; Zhao R; Wu Y; Xie ZR; Wu JM; Bowen NJ; Danaher A; Cook N; Li D; Qui M; Du Y; Fu H; Osunkoya AO; Kucuk O; Wu D
Br J Cancer; 2023 Sep; 129(5):884-894. PubMed ID: 37474721
[TBL] [Abstract][Full Text] [Related]
36. Epigenetics of Cutaneous Sarcoma.
Mashima E; Sawada Y
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008848
[TBL] [Abstract][Full Text] [Related]
37. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
38. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
39. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
